We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
OXiGENE has announced the publication of a preclinical study using local administration
of Combretastatin A4P (CA4P) in the treatment of a murine model of retinoblastoma.
Metabasis Therapeutics has announced that an article titled, "Liver-Targeted
Drug Delivery Using HepDirect Prodrugs," was published in the February
issue of The Journal of Pharmacology and Experimental Therapeutics.
Cardiome Pharma and its co-development partner Fujisawa Healthcare has announced
additional results from their recently completed 416-patient atrial arrhythmia
(AF) clinical study, called ACT 1.
Targeted Genetics, the nonprofit International AIDS Vaccine Initiative, the
Indian Council of Medical Research and National AIDS Control Organization, and
researchers at Columbus Children's Research Institute and The Children's Hospital
of Philadelphia have announced the initiation of a Phase I trial in India of
tgAAC09, an investigational recombinant adeno-associated viral vector (rAAV)-based
HIV/AIDS vaccine candidate.
The top-line outcome of Axonyx's first Phase III clinical trial with Phenserine,
in development for mild-to-moderate Alzheimer's disease (AD), showed that although
there were encouraging trends with both Phenserine 10 mg and 15 mg twice daily,
overall these did not result in a statistically significant improvement over
placebo for the protocol's primary endpoints following 26 weeks of treatment.
Ligand Pharmaceuticals has announced that Pfizer has confirmed a December
2004 FDA filing of a supplemental new drug application (NDA) for the use of
lasofoxifene for the treatment of vaginal atrophy.
Researchers have identified a promising new target in their fight against
a dangerous bacterium that sickens people in hospitals, especially people
who receive medical implants such as catheters, artificial joints and heart
valves.
NexMed has initiated the U.S. Phase I clinical study for NM10060, the company's
proprietary nail lacquer treatment for onychomycosis (nail fungal infection).